Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24928097 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL627257 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL1106426 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL23988087 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL24928198 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL24928774 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL24927970 | 1.00 | CYP2B6 (0.42) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL16197804 | 0.97 | CYP2B6 (0.41) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL23251488 | 0.97 | CYP2B6 (0.41) | CYP2B6GRIN2DGRIN3BCHRM2CHRM1 | |
| SCHEMBL179261 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | Lakewood Amedex, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| WO-2023081486-A1 | TOLL-LIKE RECEPTOR THERAPY COMBINATIONS WITH CBL-B INHIBITOR COMPOUNDS | NURIX THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230053437-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-02-23 | — | — | US | disclosed |
| WO-2023018636-A1 | COMPOUNDS THAT INHIBIT PI3K ISOFORM ALPHA AND METHODS FOR TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20230028747-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230026056-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Lakewood Amedex, Inc. | 2023-01-26 | — | — | US | disclosed |
| US-20100093716-A1 | THERAPEUTIC METHODS USING WRN BINDING MOLECULES | TRUSTEES OF BOSTON UNIVERSITY AND PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-04-15 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | ARBOR VITA CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090036376-A1 | Treatment for Anxiety | NONO INC. (CA) | 2009-02-05 | — | — | US | disclosed |
| US-20090036376-A1 | Treatment for Anxiety | NONO INC. (CA) | 2009-02-05 | — | — | US | disclosed |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | NONO INC. (CA) | 2008-09-18 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | THE PROCTER & GAMBLE COMPANY | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028747-A1 | Carboxylic Acid Containing Azetidinyl Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, LPAR5, S1PR2 | CYP2B6 4145/4885GRIN2D 1078/4885GRIN3B 392/4885 |
| US-20090062213-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | CYP2B6 4866/4885GRIN2D 2526/4885GRIN3B 967/4885 |
| US-20040097560-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, CYP51A1, CD4 | CYP2B6 12/4885GRIN2D 2745/4885GRIN3B 1939/4885 |
| US-20230053437-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | CYP2B6 2785/4885GRIN2D 4735/4885GRIN3B 3542/4885 |
| US-20070270407-A1 | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones | IL17A, IFNG, CD4 | CYP2B6 11/4885GRIN2D 2246/4885GRIN3B 1522/4885 |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | HDAC6, HDAC1, HDAC5 | CYP2B6 3541/4885GRIN2D 4092/4885GRIN3B 3744/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | CYP2B6 338/4885GRIN2D 4268/4885GRIN3B 3611/4885 |
| US-20080227684-A1 | Small Molecule Inhibitors of PDZ Interactions | PDLIM5, DAB2IP, PSD | CYP2B6 4866/4885GRIN2D 2526/4885GRIN3B 967/4885 |
| US-20230026056-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CAT, MPO, NISCH | CYP2B6 269/4885GRIN2D 4281/4885GRIN3B 3728/4885 |
| US-20100093716-A1 | THERAPEUTIC METHODS USING WRN BINDING MOLECULES | WRN, BLM, RECQL | CYP2B6 4748/4885GRIN2D 4856/4885GRIN3B 4147/4885 |
| US-20090036376-A1 | Treatment for Anxiety | GRIN2A, GRIN3A, GRIN1 | CYP2B6 4129/4885GRIN2D 35/4885GRIN3B 6/4885 |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | CYP2B6 4702/4885GRIN2D 3794/4885GRIN3B 2786/4885 |
| US-11795192-B2 | Antimicrobial compounds, compositions, and uses thereof | CAT, MPO, NISCH | CYP2B6 269/4885GRIN2D 4281/4885GRIN3B 3728/4885 |
| US-20230399355-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CAT, MPO, NISCH | CYP2B6 269/4885GRIN2D 4281/4885GRIN3B 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.